DermTech, Inc.
OTC: DMTKQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Burkhard Jansen
- Employees
- 206
- Headquarters
- San Diego, United States
- IPO year
- 2017
- Market cap
- $3.5K
- Website
- https://www.dermtech.com
Loading DMTKQ…
Loading profile data…Frequently asked questions about DMTKQ
What does DermTech, Inc. (DMTKQ) do?
DermTech, Inc. operates as a molecular diagnostics firm specializing in developing and commercializing innovative, non-invasive genomic tests designed to assist in the early detection and ongoing management of melanoma within the United States. Its flagship product, the DermTech Melanoma Test (DMT), offers a non-surgical method for improved mela...
Where does DMTKQ trade?
DermTech, Inc. (DMTKQ) trades on the Other OTC.
What sector is DMTKQ in?
DermTech, Inc. (DMTKQ) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of DermTech, Inc.?
Burkhard Jansen is the chief executive officer of DermTech, Inc. (DMTKQ).
Where is DermTech, Inc. headquartered?
DermTech, Inc. is headquartered in United States.
Does DMTKQ pay a dividend?
DermTech, Inc. (DMTKQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMTKQ go public?
DermTech, Inc. (DMTKQ) completed its initial public offering in 2017.